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Abstract
Background: Epidermal growth factor receptor (EGFR) represents a major target for current
radiosensitizing strategies. We wished to ascertain whether a correlation exists between the
expression of EGFR and treatment outcome in a group of patients with rectal adenocarcinoma who
had undergone preoperative radiotherapy (RT).
Methods: Within a six-year period, 138 patients underwent preoperative radiotherapy and
curative surgery for rectal cancer (UICC stages II-III) at our institute. Among them, 77
pretherapeutic tumor biopsies were available for semi-quantitative immunohistochemical
investigation evaluating the intensity and the number (extent) of tumor stained cells. Statistical
analyses included Cox regression for calculating risk ratios of survival endpoints and logistic
regression for determining odds ratios for the development of loco-regional recurrences.
Results: Median age was 64 years (range: 30–88). Initial staging showed 75% and 25% stage II and
III tumors, respectively. RT consisted of 44-Gy pelvic irradiation in 2-Gy fractions using 18-MV
photons. In 25 very low-rectal-cancer patients the primary tumor received a boost dose of up to
16 Gy for a sphincter-preservation approach. Concomitant chemotherapy was used in 17% of the
cases. All patients underwent complete total mesorectal resection. Positive staining (EGFR+) was
observed in 43 patients (56%). Median follow-up was 36 months (range: 6–86). Locoregional
recurrence rates were 7 and 20% for EGFR extent inferior and superior to 25%, respectively. The
Published: 20 June 2005
BMC Cancer 2005, 5:62 doi:10.1186/1471-2407-5-62
Received: 17 December 2004
Accepted: 20 June 2005
This article is available from: http://www.biomedcentral.com/1471-2407/5/62
© 2005 Azria et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 10
(page number not for citation purposes)
BMC Cancer 2005, 5:62 http://www.biomedcentral.com/1471-2407/5/62corresponding locoregional recurrence-free survival rate at two years was 94% (95% confidence
interval, CI, 92–98%) and 84% (CI 95%, 58–95%), respectively (P = 0.06). Multivariate analyses
showed a significant correlation between the rate of loco-regional recurrence and three
parameters: EGFR extent superior to 25% (hazard ratio = 7.18, CI 95%, 1.17–46, P = 0.037), rectal
resection with microscopic residue (hazard ratio = 6.92, CI 95%, 1.18–40.41, P = 0.032), and a total
dose of 44 Gy (hazard ratio = 5.78, CI 95%, 1.04–32.05, P = 0.045).
Conclusion: EGFR expression impacts on loco-regional recurrence. Knowledge of expression of
EGFR in rectal cancer could contribute to the identification of patients with an increased risk of
recurrences, and to the prediction of prognosis.
Background
In patients with rectal carcinoma, pelvic recurrence is a
major source of morbidity and mortality. Despite
improvements in surgical approaches, local recurrence
may occur in up to 30% of patients treated with surgery
including total mesorectal excision [1]. Since 2001, the
Dutch Colorectal Cancer Group Trial [2] has confirmed
that a short course of radiotherapy (RT) reduced the rate
of pelvic recurrence at 3 years, from 10.1% to 3.4%. In
addition, a meta-analysis of 19 randomized trials includ-
ing preoperative RT tends to show that it provides a gain
of three percent at 5 years in overall survival [3]. However
despite these recent intensive clinical investigations, there
is still a need to develop novel strategies in the manage-
ment of patients with locally advanced rectal cancer.
Advances in the understanding of the molecular biology
of rectal cancer have opened many new research direc-
tions. Increasing effort has been directed towards develop-
ing molecular targeted therapies or searching for
molecular markers that are useful either in predicting
treatment outcome or in selecting patients for specific
molecular targeted therapies, based on particular tumor
characteristics. None of the recent studies has identified
convincing data to warrant routine clinical application of
any marker such as p53 [4,5], or apoptosis regulators [6].
To date, no data have become available that shed light on
the impact of EGFR expression on local and distant
relapse in patients treated with preoperative RT and exten-
sive local surgery i.e. abdominoperineal excision or low
anterior resection with total mesorectal excision. We
present here the prognostic impact of EGFR expression on
locoregional recurrence in 77 patients treated with preop-
erative RT at our institute.
Methods
Patient selection and pretreatment evaluation
Within a six-year period (April 1996 and September
2002), 138 patients underwent preoperative radiotherapy
and curative surgery for rectal cancer (UICC stages II-III)
at the Val d'Aurelle Cancer Institute of Montpellier,
France. A carcinoma was considered a primary rectal car-
cinoma if it was located in the lower third (<6 cm from the
anal verge), middle third (6–12 cm), and upper third of
the rectum (above 12 cm). Pretherapy biopsies were avail-
able for analysis in 77 patients and were evaluable for the
statistical results. Diagnostic and distant disease extension
studies consisted of colorectal endoscopy with biopsies,
rectal ultrasonography (uT), presurgical carcinoembry-
onic antigen (CEA) value, abdominal and pelvic com-
puted tomography (CT) scans, chest X-ray or CT-scan and
routine laboratory studies. All patients were metastasis-
free at diagnosis.
EGFR immunohistochemical assay (IHC)
IHC of the tumor biopsies was performed by using the
Dako autostainer (DakoCytomation, Glostrup, Denmark)
and the EGFR Pharm Dx kit® K 1494 (Dako Cytomation,
Glostrup, Denmark), according to the manufacturer's
instructions with the reagents supplied with the kit.
Briefly, sections of 3 µm were mounted on silanized slides
and allowed to dry overnight at 37°C. After deparaffiniza-
tion and rehydratation, slides were incubated with 3%
hydrogen peroxide solution for 5 min. After a washing
procedure with the supplied buffer, tissue sections were
covered for 5 min with protein K solution. The slides were
then incubated for 30 min with the primary mouse anti-
EGFR MAb (clone 2-18C9), which binds to a formalin-
resistant epitope near the ligand-binding site on the extra
cellular domain of the EGFR and recognizes both wild
type and mutant type (vIII). After two rinses in buffer, the
slides were incubated with the detection system for 30
min (labeled polymer-HRP). Tissue staining was visual-
ized with a DAB substrate chromogen solution. Slides
were counterstained with hematoxylin, dehydrated, and
mounted. Negative control sections were processed with-
out the primary antibody but with an irrelevant murine
IgG1 supplied with the kit. Negative and positive control
cell slides provided with the kit EGFR Pharm Dx® were
also used, to ensure that each assay run was performed
appropriately and according to protocol specifications.
Furthermore, perineurium was considered as a positive
internal control on tumor slides. EGFR assessment was
realized according to the EGFR Pharm Dx® scoring guide-
lines. Results were reported as positive when a completePage 2 of 10
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observed in at least 1% of the tumor cells. Staining was
defined as any IHC staining of tumor cell membranes
above background level, i.e., weak, moderate, or strong.
Absence of or cytoplasm staining was reported as nega-
tive. In addition to these standardized criteria, the pathol-
ogist performed a semi-quantitative evaluation reporting
both intensity and percentage (extent) of tumor cells
staining blinded to clinical data (Figure 1).
Preoperative radiation therapy (RT) and surgical 
modalities
Patients were treated in supine position with a 3-field
(posterior and two opposed laterals) isocentric technique
using 18-MV photon beams daily, five times a week. The
daily dose at the isocenter was 2 Gy; the total dose to the
entire pelvis was 44 Gy. In 25 very low-rectal-cancer
patients, primary tumor received a boost dose of up to 16
Gy for a sphincter-preservation approach. Clinical target
volume (CTV) included the tumor and the entire rectum,
the anterior wall of the sacrum and the posterior wall of
the prostate or vagina, and the following lymph nodes:
perirectal, presacral, hypogastric, obturator, and low com-
mon iliac nodes. The planning target volume (PTV)
included the clinical target volume plus a 1–1.5-cm mar-
gin. The superior margin was the L5-S1 interspace in most
patients; in some patients with tumors very close to the
anus, however, the cranial margin was placed somewhat
lower, but always at least 5 cm above the tumor area. The
lateral margins were 1 cm outside the bony margins of the
true pelvis. The posterior margin was placed just posterior
to the sacrum. The anterior margin was dependent on the
anterior extension (gross tumor volume, GTV) of the pri-
mary tumor. Individually shaped blocks were used to
shield normal tissues. The boost volume covered the pri-
mary tumor plus a 1.5-cm margin using a 3-field (poste-
rior and oblique) technique. Standard or CT-scan
simulation was used. With the CT-scan simulator (Picker
PQ 2000 + ACQSIM), GTV, CTV, and PTV were deter-
mined as defined above, the treated volume and the irra-
diated volume according to the ICRU report 50 [7]. Fields
were marked during initial CT-scan simulation after the
ICRU reference was calculated.
Thirteen patients (17%) received concomitant chemo-
therapy. In eight patients, the chemotherapy regimen con-
sisted of continuous infusion of 200–250 mg/m2/day of
5-fluorouracil (5-FU) alone beginning on the first day of
radiation therapy, five days a week for 5 weeks. Oxalipla-
tin (40 mg/m2/day at days 1, 8, 15, 22, and 29) and leu-
covorin (100 mg/m2/day at days 1–2, 15–16, and 29–30)
were added at the same protocol of 5-FU for two and three
patients, respectively.
Patterns of EGFR expressionFigu e 1
Patterns of EGFR expression. a) Case with an extent 
positivity ≥25% with strong membrane staining of tumor 
cells. Insert and arrow: note the membranous positivity pat-
tern (immunoperoxydase × 100 and × 400). b) Case with an 
extent positivity <25% with weak membrane staining of some 
tumor cells (arrow) (immunoperoxydase × 400). c) Case 
with negative staining (immunoperoxydase × 200).Page 3 of 10
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gery was 41 days (range: 13–97). The choice of the surgi-
cal procedure was at the surgeon's discretion. In all cases,
the entire mesorectum was removed. Specimens were
inked for lateral margin determination. R1 resection was
defined as lateral clearance less than one mm.
Clinical, operative, and histopathological data were
recorded prospectively in a computerized registry data-
base including patient age, gender, tumor site, tumor
stage according to UICC stage [8], histological differentia-
tion, gross morphology, tumor size, local invasion, nodal
status and type of surgery.
Follow-up
All patients were seen on regular follow-up including clin-
ical history, physical examination, laboratory investiga-
tions, abdominal ultrasonography, chest X-ray, and
endoscopy (sigmoidoscopy after 6 months, total colonos-
copy after one year). They were followed semi-annually
during the period of 2–5 years postoperatively until death
or the closing date of the study (July 2004). Any regrowth
of tumor within the pelvis was considered as a local recur-
rence. The diagnosis of a pelvic recurrence was preferably
proven by histology and/or cytology; however, in the
majority of cases, the diagnosis was made on clinical or
radiological grounds. Data collected were entered pro-
spectively into the registry database. Median follow-up of
all patients was 36 months (range: 6–86 months).
Statistical methods
The characteristics of EGFR staining were examined for
correlation with tumor- and patient-related prognostic
factors. The cut-off of 25% of EGFR staining corresponded
to the third quartile of EGFR extent and was then selected
for all statistical correlations. Categorical variables were
reported by means of contingency tables. Furthermore, for
continuous variables the median and range were
computed.
To investigate the association between trial features, uni-
variate statistical analyses were performed using Pearson's
Chi-2 test or Fisher's exact test when applicable.
Survival times to all events were measured from the day of
surgery to the time of the event or to last news if no event
occurred. Relapse-free survival (RFS; event was all
relapse), locoregional recurrence-free survival (LRFS;
event was locoregional recurrence), and distant metasta-
sis-free survival (MFS; event was distant metastasis
relapse) rates were estimated according to the Kaplan-
Meier method. Patients not presenting the event of inter-
est were considered censored at the last known follow up
of time. Survival curves were drawn, and the logrank test
was performed to assess differences between the groups.
Cox's proportional hazards regression using a stepwise
selection procedure was used to investigate prognostic fac-
tors. Hazards ratios with 95% confidence interval, CI, are
presented.
All P values reported were two-sided, and differences were
considered as significant at the 5% level. Data were ana-
lyzed with software STATA 7.0 (Stata Corporation, Col-
lege Station, TX, USA).
Results
EGFR expression
The semi-quantitative analysis of EGFR expression is sum-
marized in Table 1. Fifty-six percent of the cases demon-
strated EGFR expression, and 44% had negative staining.
EGFR staining extent superior to 25% was observed in
26% of the cases, and the staining intensity was graded as
strong in 8%. Strong staining intensity occurred statisti-
cally more frequently in those cases with EGFR extent
≥25% than in those with <25% (P = 0.018).
EGFR and clinical characteristics of the study population
A total of 77 patients were evaluable for EGFR expression.
Median age was 64 years (range: 30–88). Twenty-six
(34%) were female and 19 (25%) were staged as stage III
patients. A majority of patients presented T3/T4 (72%)
rectal tumor. Initial tumor was located in the lower third
(n = 52, 68%), middle third (n = 17, 22%), and upper
third (n = 8, 10%) of the rectum. Twenty-five patients
(32%) received a total radiation dose of 60 Gy for a
sphincter-conserving approach. Thirteen patients (17%)
and 25 patients (32%) received preoperative concomitant
chemo-radiotherapy and adjuvant chemotherapy, respec-
tively. Microscopic incomplete surgery (R1) was achieved
in 7 patients (9%), and all corresponded to initially T4
tumors.
We compared the distribution of patients and tumor char-
acteristics and treatment according to EGFR expression
(staining intensity and extent) to assess the presence of
potential imbalances in the known prognostic variables.
Table 2 shows no significant differences between the
groups in the distribution of known clinical prognostic
indicators of loco-regional control and survival, i.e., age,
gender, stage group, tumor location, preoperative total
dose RT, concomitant chemo-radiotherapy, type of sur-
gery, resection margins. Neither was any imbalance
observed for patients who received adjuvant
chemotherapy.
EGFR expression and relapse
Overall tumor progression, caused by local recurrence
alone (n = 1, 1.3%), distant metastases alone (n = 8,
10.4%), and both of them (n = 7, 9.1%) occurred in 16
patients (20.8%).Page 4 of 10
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gional recurrence rate (20% vs 7%). The two-year LRFS
rate was 94% (92–98%) in patients with EGFR extent
<25% and 84% (58–95%) in patients with EGFR extent
≥25% with a borderline statistical difference (P = 0.06,
Figure 2).
An EGFR extent of ≥25% was associated with poorer MFS
(84% [59–95%] vs 95% [84–98%]) but the difference did
not achieve statistical significance. Metastatic evolution
corresponded to lung, liver, peritoneum, bone, and brain
in 60%, 40%, 26%, 13% and 7%, respectively. No differ-
Table 1: EGFR immunohistochemical staining characteristics in rectal-cancer patients
EGFR staining Patientsa (%) EGFR extent Patientsa (%) EGFR intensity Patientsa (%)
Negative 34 (44) - - - -
Positive 43 (56) <25% 23 (30) Weak and moderate 21 (27)
Strong 2 (3)
≥25% 20 (26) Weak and moderate 16 (21)
Strong 4 (5)
aNumber of patients
Table 2: EGFR expression and clinical characteristics of the study population
EGFR extent P value EGFR intensity P value
Parameters <25% ≥25% Negative to moderate Strong
Age (y)
≤64 26 (45.6)a 13 (65) 36 (50.7) 3 (50)
>64 31 (54.4) 7 (35) 0.14 35 (49.3) 3 (50) 0.97
Gender
Male 38 (66.7) 13 (65) 47 (66.2) 4 (66.7)
Female 19 (33.3) 7 (35) 0.89 24 (33.8) 2 (33.3) 0.98
Stage groupb
II 43 (75.4) 15 (75) 54 (76.1) 4 (66.7)
III 14 (24.6) 5 (25) 0.97 17 (23.9) 2 (33.3) 0.61
Tumor location
Lower third 39 (68.4) 13 (65) 46 (64.8) 6 (100)
Middle third 12 (21.1) 5 (25) 17 (23.9) -
Upper third 6 (10.5) 2 (10) 0.96 8 (11.3) - 0.21
Preoperative
RT-CTc 8 (14) 5 (25) 0.26 11 (15.5) 2 (33.3) 0.26
Preoperative RT
44 Gy 40 (70.2) 12 (60) 48 (67.6) 4 (66.7)
60 Gy 17 (28.8) 8 (40) 0.40 23 (32.4) 2 (33.3) 0.96
Type of surgeryd
AP 46 (80.7) 17 (85) 58 (81.7) 5 (83.3)
LAR 11 (19.3) 3 (15) 0.67 13 (18.3) 1 (16.7) 0.92
Resection
Margins
- 52 (93) 17 (85) 63 (90) 6 (100)
+ 4 (7) 3 (15) 0.30 7 (10) - 0.41
Adjuvant
chemotherapy 16 (28.1) 9 (45) 0.16 24 (33.8) 1 (16.7) 0.39
aData are presented as number of patients, with the percentage in parentheses.
bAccording to AJCC (American Joint Committee on Cancer) 1997.
cPreoperative chemo-radiotherapy.
dAP, abdominoperineal excision; LAR, low anterior resectionPage 5 of 10
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according to EGFR status.
Patients with strong EGFR staining intensity had a higher
loco-regional recurrence rate (17% vs 10%) and a poorer
RFS than those with negative to moderate staining inten-
sity but without significant statistical difference.
Univariate analysis did not show any significant associa-
tion of tumor local recurrence with age (P = 0.48), gender
(P = 0.81), UICC stage III (P = 0.08), tumor location (P =
0.60), preoperative chemotherapy (P = 0.73), preopera-
tive RT (P = 0.26), type of surgery (P = 0.66), resection
margins (P = 0.10), and adjuvant chemotherapy (P =
0.75). To adjust for prognostic factors, the clinical param-
eters described in Table 2 were included in the multivari-
ate analysis using the Cox proportional hazards model,
i.e., EGFR extent (<25% vs ≥25%), resection (complete
[R0] vs R1), tumor stage (II vs III), preoperative total dose
RT (44 vs 60 Gy), gender, tumor location (lower third vs
other thirds), type of surgery, resection margins, age (≤64
vs >64 years old), preoperative concomitant chemo-radi-
otherapy (no vs yes), EGFR intensity (negative to moder-
ate vs strong), delay from the last day of RT to the day of
surgery (≤41 vs >41 days) and uT.
EGFR extent expression, R1 resection, and 44-Gy total
dose radiation were the independent prognostic factors
that predicted locoregional failure with P values of 0.037,
0.032, and 0.045, respectively (Table 3). For both RFS and
MFS, stage III tumor was detected as an independent prog-
nostic factor with P values of 0.024 (hazard ratio = 4.08,
CI 95%, 1.21–13.82) and 0.023 (hazard ratio = 4, CI 95%,
1.22–13.13), respectively. Concomitant preoperative
chemo-radiotherapy was detected as a potential prognos-
tic factor for RFS and MFS but statistical analysis showed
only a trend towards significance P = 0.057 and 0.070,
respectively. Margin resection <1 mm was also detected as
a significant prognostic factor for MFS (hazard ratio =
5.03, CI 95%, 1.02–24.78, P = 0.047). EGFR expression
predicted neither RFS (hazard ratio = 1.11, CI 95%, 0.28–
Locoregional recurrence-free survival curves according to epidermal growth factor receptor (EGFR) expression extentFigu  2
Locoregional recurrence-free survival curves according to epidermal growth factor receptor (EGFR) expression extent.Page 6 of 10
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5.41, P = 0.753).
Discussion
The identification of parameters that reflect biological
behavior of individual cancer tissues correlating with
tumor aggressiveness is a key determinant of prognosis
and a fundamental issue for the improvement of cancer
therapy. Despite recent progress in defining the molecular
mechanisms of cancer development and tumor progres-
sion, only a few individual biomarkers providing prog-
nostic information have been identified. Among them,
the EGFR pathways attracted the most attention of cancer
investigators.
EGFR (HER1), a transmembrane glycoprotein, is a mem-
ber of the large receptor tyrosine family encoded by a gene
located in human chromosome 7p12. EGFR exists in inac-
tive monomer form or in active dimer form. Dimerization
can take place between different receptors in order to
develop homologue (homodimers) or heterologue (het-
erodimers) dimers [9]. In either normal or malignant
cells, the activation of EGF receptor cascades may have
multiple consequences such as cell growth, differentia-
tion, and proliferation. EGF receptor cascades may also
promote malignant transformation, angiogenesis, and/or
metastatic dissemination [10,11].
In addition, the cell membrane has been known for some
time to be a secondary target for ionizing radiation. This
phenomenon may provoke the pathways of mitogen-acti-
vated protein kinase (MAPK), phosphatidyl inositol-3-
phosphate kinase (PI3K), and MAPK8 activation [12],
which can modulate cell proliferation or death. Preclinical
and clinical studies associate EGFR expression with radi-
oresistance [13-16]. Ionizing radiation produces several
types of cellular response via activation of multiple trans-
duction pathways resulting in cell death, differentiation,
or proliferation. Following irradiation, the MAPK path-
way was recently reported to be a cellular "SOS" signal ini-
tiator starting from EGF receptors [17]. MAPK pathway
activation via EGFR receptors was reported in many
malignant human cell lines [17-19]. This activation is
similar to the one produced by physiological concentra-
tions of EGF (0.1 nM), and seems to act as a radioprotec-
tor [16,17,19,20]. Moreover, it has been recently shown
that EGF-receptor and MAPK signal pathway activation
following ionizing radiation depends on the proteolytic
clivage of TGFβ precursor and functional activation of
autocrine TGFβ [21]. STAT-3 signal pathway activation by
phosphorylation via EGF receptors can be initiated by
ionizing radiation, and it results with a radioprotective
effect by apoptosis inhibition [22-24]. An inverse relation
between the number of EGF receptors and tumor radio-
curability is reported in several murine cell lines. In these
models, radiation-induced apoptosis was decreased when
important levels of EGF receptor were expressed on the
cells [25,26]. Clinical consequences of these findings
would be tailoring treatment according to a simple predic-
tive assay of radiosensitivity based on the EGF-receptor
expression. Clinical data pertaining to the relationship
between EGFR expression and the success of radiotherapy
are sparse and equivocal. Nevertheless, with respect to
squamous-cell cancer of the head and neck, EGFR is
among the best-studied examples [27-33], and positive
and negative correlations between EGFR levels and tumor
recurrences were reported in laryngeal cancers after radio-
therapy [34-36]. The relationship of EGFR levels to the
prognosis in unresectable pharyngeal or nasopharyngeal
cancer patients treated by chemo-radiotherapy was
recently reported [37-39].
In colorectal cancer, EGFR expression was evaluated in
resected tumors [40]. The authors found significantly
higher EGFR levels in stage III cancers than in stages I and
II. It was then concluded that high EGFR expression is
associated with poor prognosis. Another group [41],
found 72 cases of EGFR-positive expression in 82 resected
Table 3: Cox multivariate regression analysis for loco-regional recurrence-free survival (LRFS)a
Prognostic variable Hazard ratio 95% CIb Pvalue
EGFR extent <25%
≥25%
1
7.18
1.12 to 46 0.037
Resection R0
R1
1
6.92
1.18 to 40.42 0.032
Preoperative RT 60 Gy
44 Gy
1
5.78
1.04 to 32.06 0.045
aResults were adjusted on tumor stage, gender, type of surgery, surgical margin, age, preoperative radio-chemotherapy, EGFR intensity, delay from 
radiotherapy to surgery, and uT
bCI, confidence intervalPage 7 of 10
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expression (>50%) revealed significant differences in sur-
vival times. In our study, a significant correlation between
the positive tumor cell percentage greater than 25% and
the rate of locoregional recurrence was detected (P =
0.037).
We did not assess the predictive value of EGFR on tumor
response after preoperative treatment. This question was
recently tackled by Giralt et al [42]. The authors analyzed
EGFR expression of 45 locally advanced-rectal-cancer
patients treated with preoperative radiotherapy and total
mesorectal resection. Immunochemistry for EGFR was
determined at the preradiation diagnostic biopsy and in
the resected specimens. EGFR positivity was observed in
29 of 45 tumors (64%) and was associated with neither
clinical tumor stage nor clinical nodal stage. The overall
response rate was 34% in EGFR positive patients vs. 62%
in those who did not express EGFR (P = 0.07). Only one
of the seven pathologic complete remission patients was
EGFR positive (P = 0.003). The link between the positive
EGFR expression and the microscopic response on surgi-
cal specimen seems to be logical, but we fail to assess it in
our series. Such a relationship should be based on a large
tumor sampling and needs a very strict procedure at the
macroscopic level, to ensure that the whole tumor is ana-
lyzed after a neoadjuvant treatment. An exhaustive tissue
material should allow a precise analysis of the entire spec-
trum of tumor regression, i.e., complete, partial or none,
as it has been proposed by Dvorack et al [43]. It should
then be of interest to correlate these well documented his-
topathological data with biological parameters such as
EGFR.
In our study EGFR expression was not found to be an
independent prognostic factor for overall survival in
patients with rectal cancer. Other studies, described above
[40,41], have reported variable results making it difficult
to draw firm conclusions about a possible relationship
between EGFR expression and overall survival. Probably,
the variation in results is due to (i) the use of different lab-
oratory tests, (ii) varying extent of follow-up, and (iii) het-
erogeneity in the population of colon- and rectum-cancer
patients. (i) EGFR assessment in previous studies was
obtained by using different antibodies, different methods
of antigen retrieval, and different cut-off values. In this
study, we used uniform reagents provided by a kit allow-
ing minimized variations in results and a reproducible
method. Therefore, our results detected a low percentage
of EGFR immunopositivity (56%) as compared with other
colorectal cancer trials [44] probably due to the numerous
IHC techniques. (ii) In this study we did not have a suffi-
ciently long follow-up to give definitive conclusions on
the prognostic impact on EGFR expression and overall
survival. In fact, our analysis was only based on a group of
patients with rectal carcinoma, a disease with a natural
history different from that of colon carcinoma especially
with respect to the tendency to recur locally. (iii) Reasons
for recurrence after curative resection for colorectal carci-
noma are not completely clear. Several theories have been
put forward including, amongst others, microscopic
deposits in the lymphatics, inadequate distant and lateral
resection margins, exfoliated tumor cells at time of sur-
gery, presence of malignant cells in the anastomosis and,
finally, tumor aggressiveness related to biological behav-
iour. It is known that reported recurrence after resection
for rectal carcinoma is commonly higher than after colon
carcinoma [45,46], and differences in prognosis have also
been reported between high and low rectal carcinomas
[47]. Risk factors that have previously been associated
with increased recurrence rates include amongst others
patient age, gender, tumor stage, site of lesion (colon vs
rectum), infiltration of adjacent organs, histopathological
criteria, tumor size, lymph-node involvement and radial
resection margins [45,46,48-50]. In rectal cancer, in par-
ticular, the impact of surgery and adequate lymph-node
dissection related to the risk of local recurrence have been
highlighted [51]. Several studies have evaluated the prog-
nostic significance of EGFR on survival in colorectal can-
cer but, to our knowledge, not specifically focusing on
rectal cancer recurrence.
In our study, multivariate statistical model identified
EGFR expression as a significant independent predictor of
recurrence following preoperative and curative surgery for
rectal cancer. Two possible explanations for this relation-
ship are to be considered. Firstly, EGFR overexpressing
tumors exhibit a more aggressive behavior leading to
more pelvic recurrences and in a lesser extent to more dis-
tant metastases. A second possible explanation is that
EGFR overexpressing tumors present decreased intrinsic
radiosensitivity as explained at the first part of this discus-
sion and lead to more pelvic recurrences. This explanation
is supported by the fact that the majority of the observed
recurrences in our study appeared in the irradiated areas.
Therapeutic approaches targeting EGFR signaling path-
ways either alone or in combination with radiation or
cytotoxic agents are being intensively investigated [52].
Strategies that are in various stages of development
include blockade of the extracellular receptor domain [44]
and inhibition of the intracellular tyrosine kinase activity
[53]. Data presented in Figure 2 suggest that tumor radia-
tion-sensitization through the inhibition of EGFR
signaling could yield a therapeutic gain by increasing the
locoregional control rate in patients with EGFR-overex-
pressing rectal cancer.Page 8 of 10
(page number not for citation purposes)
BMC Cancer 2005, 5:62 http://www.biomedcentral.com/1471-2407/5/62Conclusion
Knowledge of expression of EGFR in rectal cancer can con-
tribute to the identification of patients with an increased
risk of recurrences. Our results have to be related to several
confounding factors such as the small number of events
and the retrospective approach. Nevertheless, the poten-
tial of introducing routine EGFR immunohistochemistry
as a diagnostic tool into the clinical practice of rectal can-
cer management still has to be undertaken, and may allow
clinicians to deliver targeted therapies even in patients
with a poorer prognosis.
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